PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Edward M. Fitzgerald filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing stock options and convertible preferred stock holdings in Parabilis Medicines, Inc. This is a routine SEC filing required upon becoming an insider; it contains no material financial events or changes in the company's operations.
Actionable Insight
This is a routine initial ownership filing with no trading or corporate action. No immediate trading signal. Monitor for any subsequent Form 4 filings or IPO-related conversion events.
Key Facts
- Filing type: Form 3 (initial statement of beneficial ownership) filed by Edward M. Fitzgerald.
- Discloses stock options to buy: 16,245 shares at $1.85 (expiring 2027-07-30), 16,245 shares at $4.82 (expiring 2031-05-12), 32,490 shares at $3.14 (expiring 2036-02-23).
- Holds convertible Series B Preferred (5,539 shares common underlying), Series C Preferred (3,878 shares common underlying), and Series F Preferred (5,271 shares common underlying).
- Conversion ratios: Series B 1:1.0389, Series C 1:1.0578, Series F 1:0.6498; all automatically convert to common stock upon IPO closing.
- Filed concurrently with a Limited Power of Attorney designating Teresa Jurgensen and Thomas Kotarakos to execute future Section 16 filings.
Financial Impact
No monetary value disclosed; the options and preferred shares represent insider equity holdings. No transaction or cash flow involved.
Risk Factors
- No material risks identified from this filing alone.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-264573 |
| Document: 0001193125-26-264573-index-headers.html | 0001193125-26-264573 |
| Document: 0001193125-26-264573-index.html | 0001193125-26-264573 |
| Document: 0001193125-26-264573.txt | 0001193125-26-264573 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access